Inside the research
AbbVie Inc.
ABBV Research profile · latest available data
Price overview
$264.34
▼ -0.78 (-0.3%)
| 52w hi | $265.97 |
|---|---|
| 52w lo | $195.99 |
| Vol | 2.54M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.40
| Short | +0.18 |
|---|---|
| Medium | +0.52 |
| Long | +0.58 |
computed 2026-09-27
Key fundamentals
AbbVie Inc.
Healthcare · Drug Manufacturers - General
| Market cap | $467.12B |
|---|---|
| Enterprise value | $531.48B |
| Trailing P/E | 74.46x |
| Forward P/E | 16.26x |
| EV / EBITDA | 17.28x |
| P / S (ttm) | 7.25x |
| Profit margin | 9.8% |
| Revenue growth | +10.2% |
| Earnings growth | +290.4% |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.34 | |
| Sector | +0.08 | |
| Technical | +0.18 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Risk Metrics
| Beta vs SPX | 0.27 |
|---|---|
| Corr SPX | 0.16 |
| Annual vol | 27.2% |
| Annual ret | +19.3% |
| Sharpe | 0.71 |
| Max DD | -21.5% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $252.23 |
|---|---|
| High / Low | $328.00 / $184.00 |
| Median | $253.50 |
| Analysts | 30 |
| Strong Buy | 8 | |
|---|---|---|
| Buy | 16 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-04 | Evercore ISI Group | → Outperform |
| 2026-05-01 | Guggenheim | → Buy |
| 2026-04-30 | Morgan Stanley | → Overweight |
| 2026-04-30 | Cantor Fitzgerald | → Overweight |
| 2026-04-30 | Canaccord Genuity | → Buy |
| 2026-04-23 | Piper Sandler | → Overweight |
Officers & Board
| CEO | Robert A. Michael since 2024 |
|---|---|
| Director | Robert A. Michael since 2024 |
| Director | Jennifer L. Davis since 2023 |
| Director | Susan Quaggin since 2023 |
| Director | Tom Freyman since 2020 |
| Director | Becky Roberts since 2018 |
| Director | Melody Meyer since 2017 |
| Director | Brett Hart since 2016 |
| Director | Glenn Tilton since 2013 |
| Director | Roxanne Austin since 2013 |
| Director | Richard A. Gonzalez since 2013 |
| Director | Willie Burnside since 2013 |
| Director | Robert Alpern since 2013 |
| Director | Edward J. Rapp since 2013 |
| Director | Rick Waddell since 2012 |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Other Material Event, Exhibits | read |
| 2026-07-31 | Earnings Release, Exhibits | read |
| 2026-07-06 | Earnings Release, Exhibits | read |
| 2026-06-22 | Reg FD Disclosure, Exhibits | read |
| 2026-05-12 | Shareholder Vote | read |
| 2026-04-29 | Earnings Release, Exhibits | read |
| 2026-04-03 | Earnings Release, Exhibits | read |
| 2026-03-04 | Other Material Event, Exhibits | read |
| 2026-02-26 | Other Material Event, Exhibits | read |
| 2026-02-04 | Earnings Release, Exhibits | read |
| 2026-01-07 | Earnings Release, Exhibits | read |
| 2025-10-31 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-08 | FALK THOMAS J | Director | Grant | 1.12K | — |
| 2026-05-08 | FREYMAN THOMAS C | Director | Grant | 1.12K | — |
| 2026-05-08 | Hart Brett J | Director | Grant | 1.12K | — |
| 2026-05-08 | WADDELL FREDERICK H | Director | Grant | 1.12K | — |
| 2026-05-08 | RAPP EDWARD J | Director | Grant | 1.12K | — |
| 2026-05-08 | Quaggin Susan E | Director | Grant | 1.12K | — |
| 2026-05-08 | MEYER MELODY B | Director | Grant | 1.12K | — |
| 2026-05-08 | Roberts Rebecca B | Director | Grant | 1.12K | — |
| 2026-03-04 | Purdue David Ryan | Officer, SVP, Controller | Sell | 5.23K | $1.22M |
| 2026-03-02 | Siatis Perry C | Officer, EVP, GC AND SECR | Sell | 5.78K | $1.35M |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.4% |
| HHI | 4,525 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $20.78B | 82.60M |
| Fidelity / FMR LLC | $5.23B | 20.77M |
| Capital Research / Capital World | $3.69B | 14.68M |
| Citadel Advisors | $1.65B | 6.56M |
| Millennium Management | $569.56M | 2.26M |
| AQR Capital Management | $507.11M | 2.02M |
| T. Rowe Price Group | $3.71M | 14.75M |
| Bridgewater Associates | $2.96M | 11.78K |
As of 2026-06-30
Dividends
| Yield (TTM) | 1.93% |
|---|---|
| $ / share (TTM) | $5.10 |
| 5y CAGR | +6.8% |
Annual dividend per share
| 2021 | $5.20 |
|---|---|
| 2022 | $5.64 |
| 2023 | $5.92 |
| 2024 | $6.20 |
| 2025 | $6.56 |
| 2026 | $3.46 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $113.27K | Department of Veterans Affairs | PHARM - VYALEV |
| $68.99K | Department of Veterans Affairs | FOSCARBIDOPA 12MG/ML/FOSLEVODOPA 240MG/ML INJ,SOLN - 4 MONTH SUPPLY |
| $62.19K | Department of Veterans Affairs | VYALEV - ANTIPARKINSON AGENTS |
| $51.84K | Department of Health and Human Services | ABBVIE US LLC, ALLERGAN BREAST IMPLANT SUPPLIES, PIMC, YEAR 3 |
| $49.85K | Department of Health and Human Services | BPA CALL 25F28002 YEAR 2 ABBVIE US LLC PIMC ALLERGAN BREAST IMPLANT SUPPLIES |
| $47.09K | Department of Veterans Affairs | PROSTHETICS:SURGICAL BREAST IMPLANTS |
| $46.18K | Department of Health and Human Services | ABBVIE US LLC, ALLERGAN BREAST IMPLANT SUPPLIES, PIMC, BPA CALL, YEAR 1, 24F2800 |
| $41.53K | Department of Veterans Affairs | PHARM - VYALEV |
SEC Filings
The Long Run
FY 2013–2025 · 13 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $61.16B | +24.3% | |
| Gross profit | $12.07B | +11.1% | |
| Operating income | $15.07B | +8.3% | |
| Net income | $4.23B | -3.7% | |
| Cash from ops | $19.03B | +11.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $265.49 | $266.00 | $262.59 | $264.34 | 2.54M |
| Sep 24 | $265.37 | $267.41 | $263.09 | $265.12 | 3.46M |
| Sep 23 | $266.00 | $269.39 | $263.59 | $265.08 | 3.47M |
| Sep 22 | $263.10 | $266.82 | $262.15 | $265.21 | 2.77M |
| Sep 21 | $263.07 | $266.60 | $261.23 | $264.48 | 3.43M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →